409 related articles for article (PubMed ID: 20302641)
1. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
[TBL] [Abstract][Full Text] [Related]
2. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes).
Stohl W
Arthritis Res Ther; 2010; 12(2):111. PubMed ID: 20441604
[TBL] [Abstract][Full Text] [Related]
3. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.
Yaccoby S; Pennisi A; Li X; Dillon SR; Zhan F; Barlogie B; Shaughnessy JD
Leukemia; 2008 Feb; 22(2):406-13. PubMed ID: 18046446
[TBL] [Abstract][Full Text] [Related]
4. TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis.
Qin Q; Chang Y; Wang D; Wu Y; Zhang LL; Wei W
Int Immunopharmacol; 2011 Dec; 11(12):2167-75. PubMed ID: 21996540
[TBL] [Abstract][Full Text] [Related]
5. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
[TBL] [Abstract][Full Text] [Related]
6. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
[TBL] [Abstract][Full Text] [Related]
7. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
[TBL] [Abstract][Full Text] [Related]
8. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
Vincent FB; Saulep-Easton D; Figgett WA; Fairfax KA; Mackay F
Cytokine Growth Factor Rev; 2013 Jun; 24(3):203-15. PubMed ID: 23684423
[TBL] [Abstract][Full Text] [Related]
9. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases.
Roschke V; Sosnovtseva S; Ward CD; Hong JS; Smith R; Albert V; Stohl W; Baker KP; Ullrich S; Nardelli B; Hilbert DM; Migone TS
J Immunol; 2002 Oct; 169(8):4314-21. PubMed ID: 12370363
[TBL] [Abstract][Full Text] [Related]
10. To target or not to target APRIL in systemic lupus erythematosus: that is the question!
Morel J; Hahne M
Arthritis Res Ther; 2013 Feb; 15(1):107. PubMed ID: 23438039
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.
Marsters SA; Yan M; Pitti RM; Haas PE; Dixit VM; Ashkenazi A
Curr Biol; 2000 Jun; 10(13):785-8. PubMed ID: 10898980
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
14. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation.
Kim J; Gross JA; Dillon SR; Min JK; Elkon KB
Autoimmunity; 2011 Mar; 44(2):69-81. PubMed ID: 21250838
[TBL] [Abstract][Full Text] [Related]
15. [Progress in the study of BLyS and APRIL on regulating T cell responses in rheumatoid arthritis].
Chang Y; Wei W
Yao Xue Xue Bao; 2013 Jul; 48(7):979-85. PubMed ID: 24133964
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
[TBL] [Abstract][Full Text] [Related]
17. The role of the BAFF/APRIL system in the T cell-independent specific response to blood stage Plasmodium falciparum hemozoin.
Dechkajorn W; Benjathummarak S; Kumsiri R; Maneerat Y
Cytokine; 2018 Nov; 111():445-453. PubMed ID: 29884307
[TBL] [Abstract][Full Text] [Related]
18. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.
Gordon C; Wofsy D; Wax S; Li Y; Pena Rossi C; Isenberg D
Arthritis Rheumatol; 2017 Jan; 69(1):122-130. PubMed ID: 27390168
[TBL] [Abstract][Full Text] [Related]
19. No interactions between heparin and atacicept, an antagonist of B cell survival cytokines.
Kowalczyk-Quintas C; Willen D; Willen L; Golob M; Schuepbach-Mallepell S; Peter B; Eslami M; Vigolo M; Broly H; Samy E; Yalkinoglu Ö; Schneider P
Br J Pharmacol; 2019 Oct; 176(20):4019-4033. PubMed ID: 31355456
[TBL] [Abstract][Full Text] [Related]
20. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
